Page last updated: 2024-10-16

gamma-aminobutyric acid and Affective Disorders

gamma-aminobutyric acid has been researched along with Affective Disorders in 79 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

ExcerptRelevanceReference
"There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus."9.12Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007)
"To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus."9.12Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007)
"This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)."9.11Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004)
" Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported."9.08Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997)
"The efficacy of a new drug, pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg), was studied on 100 patients affected by insomnia, associated with mood disorders."9.08Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders. ( Negri, L, 1997)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."8.81Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Pharmacological evidence suggests the involvement of gamma-aminobutyric acid (GABA) perturbation in the etiology of mood disorders."7.72Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. ( Iwayama-Shigeno, Y; Watanabe, A; Yamada, K; Yoshikawa, T, 2003)
"Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting."7.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder."7.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)."7.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting."7.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder."7.69Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996)
" Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders."7.67Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988)
"Pregabalin efficaciously treated the neuropathic pain of PHN."6.71Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004)
" A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks."6.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia."6.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Abnormalities of GABAergic (gamma-aminobutyric acidergic) systems may play a role in schizophrenia and mood disorders."5.41Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. ( Simmonite, M; Steeby, CJ; Taylor, SF, 2023)
"Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder."5.30Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"To assess the roles of substance P in neurologic or psychiatric illnesses, effects of acute or chronic (40- or 80-day dietary) treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content were investigated in the rat brain."5.27Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988)
"The aims of the present study were to investigate the main demographic and clinical characteristics, comorbidity patterns, use in association and tolerability of pregabalin in a sample of patients with affective disorders, and to compare demographic and clinical variables of the groups divided, according to the treatment pregabalin was associated with."5.16Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. ( Altamura, AC; Arici, C; Buoli, M; Camuri, G; Dell'Osso, B; Dobrea, C, 2012)
"One hundred and fourteen consecutive outpatients, with anxiety and/or depressive disorders with or without comorbidity, were started on pregabalin, assessed and interviewed and their demographic data, associated therapy, tolerability and side effects collected over an observational period of 6 months."5.16Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. ( Altamura, AC; Arici, C; Buoli, M; Camuri, G; Dell'Osso, B; Dobrea, C, 2012)
"To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus."5.12Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007)
"There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus."5.12Treatment of tinnitus with gabapentin: a pilot study. ( Hannley, MT; Stinnet, S; Tucci, DL; Witsell, DL, 2007)
"This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)."5.11Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004)
" We tested this hypothesis by reviewing the multiple mechanisms of action of topiramate (TPM) and levetiracetam (LEV) together with clinical behavioral side effects of patients who had been treated with TPM and LEV in a tertiary referral center for epilepsy."5.11Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. ( Aldenkamp, AP; Bootsma, HP; Kessels, AG; Leenen, LA; Leonard, BE; Majoie, HJ; Roberts, GM, 2005)
" Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported."5.08Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997)
"The efficacy of a new drug, pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg), was studied on 100 patients affected by insomnia, associated with mood disorders."5.08Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders. ( Negri, L, 1997)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."4.81Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders."4.79GABA and mood disorders: a brief review and hypothesis. ( Petty, F, 1995)
" This protocol was validated by determining the postmortem cerebrospinal fluid (CSF) glutamic acid (Glu) and γ-aminobutyric acid (GABA) levels of 8 major depressive disorder (MDD) patients, 9 bipolar disorder (BD) patients, and 19 well-matched controls, while also testing the plasma and CSF AA levels of living MDD patients."3.83A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression. ( Bao, AM; Wu, JL; Wu, SH; Yu, SY, 2016)
" We investigated the gamma-aminobutyric acid A (GABA(A)) delta receptor subunit gene, GABRD, as a susceptibility gene to childhood-onset mood disorders (COMD) because of substantial evidence implicating GABAergic dysfunction in mood disorders and the position of this gene near the 1p36 linkage region."3.76Association of the GABRD gene and childhood-onset mood disorders. ( Baji, I; Barr, CL; Benák, I; Besnyo, M; Daróczi, G; Dombovári, E; Feng, Y; Gádoros, J; Kaczvinszk, E; Kapornai, K; Kennedy, JL; Kiss, E; Kothencné, VO; Kovacs, M; Mayer, L; Székely, J; Tamás, Z; Vetró, A, 2010)
"Pharmacological evidence suggests the involvement of gamma-aminobutyric acid (GABA) perturbation in the etiology of mood disorders."3.72Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. ( Iwayama-Shigeno, Y; Watanabe, A; Yamada, K; Yoshikawa, T, 2003)
"Gabapentin is an anticonvulsant agent, also effective in the treatment of mood disorders and anxiety disorders."3.71Treatment of alcohol withdrawal with gabapentin. ( Bozikas, V; Gamvrula, K; Karavatos, A; Petrikis, P; Savvidou, I, 2002)
"Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders."3.70GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. ( Catalano, M; Cusin, C; Di Bella, D; Lattuada, E; Lilli, R; Macciardi, F; Serretti, A; Smeraldi, E, 1998)
"Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting."3.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder."3.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"All charts of patients meeting DSM-IV criteria for bipolar disorder or unipolar major depressive disorder treated with gabapentin in a private psychiatric practice were reviewed and clinical response was assessed retrospectively using the Clinical Global Impressions scale for Improvement (CGI-I)."3.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"To determine if gabapentin is effective either as adjunctive treatment or as monotherapy for major affective disorders in a naturalistic setting."3.70Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"Low levels of gamma-aminobutyric acid (GABA) in plasma have been associated with the presence of mood disorders in patients with major depressive disorder."3.69Plasma levels of gamma-aminobutyric acid and panic disorder. ( Davis, LL; Germine, M; Goddard, AW; Kramer, GL; Narayan, M; Petty, F; Woods, SW, 1996)
" Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders."3.67Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988)
"Pregabalin efficaciously treated the neuropathic pain of PHN."2.71Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004)
"In DSM-5, catatonia syndrome may be diagnosed as a specifier to major mood disorders, psychotic disorders, general medical conditions, and as catatonia not otherwise specified."2.53Catatonia. ( Strik, W; Walther, S, 2016)
"Catatonia is potentially life threatening."2.53Catatonia. ( Strik, W; Walther, S, 2016)
" Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function."2.44GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. ( Sanacora, G; Saricicek, A, 2007)
"Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter present almost exclusively in the central nervous system (CNS), distributed across almost all brain regions, and expressed in interneurons modulating local circuits."2.42GABAergic dysfunction in mood disorders. ( Barale, F; Brambilla, P; Perez, J; Schettini, G; Soares, JC, 2003)
"The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common."2.41Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000)
"Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia."2.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
" A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks."2.41Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
" Neurochemically, decreased 5-HT uptake in the platelet, increased 5-HT2 receptor in the platelet and cortex of suicides, increased beta receptor in the brains of suicide, functional abnormality of alpha 2 receptor in clonidine, DMI test, GABAB receptor up-regulation after chronic administration of antidepressants and mood stabilizers, participation of neuropeptide Y, and abnormality of HPA axis were recognized."2.39[Etiology of affective disorders]. ( Kariya, T; Shinohara, M, 1994)
"Gabapentin is an anticonvulsant agent, also effective in the treatment of mood disorders and anxiety disorders."1.31Treatment of alcohol withdrawal with gabapentin. ( Bozikas, V; Gamvrula, K; Karavatos, A; Petrikis, P; Savvidou, I, 2002)
"Gabapentin was moderately to markedly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder."1.30Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998)
"To assess the roles of substance P in neurologic or psychiatric illnesses, effects of acute or chronic (40- or 80-day dietary) treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content were investigated in the rat brain."1.27Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988)

Research

Studies (79)

TimeframeStudies, this research(%)All Research%
pre-199010 (12.66)18.7374
1990's16 (20.25)18.2507
2000's28 (35.44)29.6817
2010's21 (26.58)24.3611
2020's4 (5.06)2.80

Authors

AuthorsStudies
Simmonite, M1
Steeby, CJ1
Taylor, SF2
Reddy-Thootkur, M1
Kraguljac, NV1
Lahti, AC1
Felice, D1
Cryan, JF1
O'Leary, OF1
Sbrini, G1
Brivio, P1
Bosch, K1
Homberg, JR1
Calabrese, F1
Wilkinson, ST1
Sanacora, G6
Wilczyńska, K1
Simonienko, K1
Konarzewska, B1
Szajda, SD1
Waszkiewicz, N1
Demeter, E1
Phan, KL1
Tso, IF1
Welsh, RC1
Stan, AD1
Schirda, CV1
Bertocci, MA1
Bebko, GM1
Kronhaus, DM1
Aslam, HA1
LaBarbara, EJ1
Tanase, C1
Lockovich, JC1
Pollock, MH1
Stiffler, RS1
Phillips, ML1
Paknejad, B1
Kebriaeezadeh, A1
Ghahremani, MH1
Gharghabi, M1
Ostad, SN1
Kalia, M1
Costa E Silva, J1
Bogan, RK1
Lee, DO1
Buchfuhrer, MJ1
Jaros, MJ1
Kim, R1
Shang, G1
Kim, S1
Hwang, Y1
Webster, MJ1
Lee, D1
Hantsoo, L1
Epperson, CN2
Wu, JL1
Yu, SY1
Wu, SH1
Bao, AM1
Greenberg, GD1
Crabbe, JC1
Walther, S1
Strik, W1
Hamada, Y1
Yamashita, A1
Tamura, H1
Narita, M2
Kuzumaki, N1
Sümegi, A1
Pinna, G1
Costa, E1
Guidotti, A1
Lee, CH1
Hwang, IK1
Choi, JH1
Yoo, KY1
Han, TH1
Park, OK1
Lee, SY1
Ryu, PD1
Won, MH1
Moore, AR1
Straube, S1
Paine, J1
Phillips, CJ1
Derry, S1
McQuay, HJ1
Feng, Y1
Kapornai, K1
Kiss, E1
Tamás, Z1
Mayer, L1
Baji, I1
Daróczi, G1
Benák, I1
Kothencné, VO1
Dombovári, E1
Kaczvinszk, E1
Besnyo, M1
Gádoros, J1
Székely, J1
Kovacs, M1
Vetró, A1
Kennedy, JL1
Barr, CL1
Sibille, E1
Morris, HM1
Kota, RS1
Lewis, DA1
Treccani, G1
Popoli, M1
Mease, PJ1
Dundon, K1
Sarzi-Puttini, P1
Femenía, T1
Gómez-Galán, M1
Lindskog, M1
Magara, S1
Dobrea, C1
Buoli, M1
Arici, C1
Camuri, G1
Dell'Osso, B1
Altamura, AC1
Drabkin, R1
Calhoun, L1
Chang, L1
Cloak, CC1
Ernst, T1
Taylor, M1
Bhagwagar, Z1
Cowen, PJ1
Sharp, T1
Brambilla, P1
Perez, J1
Barale, F1
Schettini, G1
Soares, JC1
Yamada, K1
Watanabe, A1
Iwayama-Shigeno, Y1
Yoshikawa, T1
Joffe, H1
Soares, CN1
Cohen, LS1
Rothman, DL1
Mason, G1
Krystal, JH3
Sabatowski, R1
Gálvez, R1
Cherry, DA1
Jacquot, F1
Vincent, E1
Maisonobe, P1
Versavel, M1
Kendell, SF1
Roberts, GM1
Majoie, HJ1
Leenen, LA1
Bootsma, HP1
Kessels, AG1
Aldenkamp, AP1
Leonard, BE1
Van Den Bogaert, A1
Del-Favero, J1
Van Broeckhoven, C1
Witsell, DL1
Hannley, MT1
Stinnet, S1
Tucci, DL1
Victorri-Vigneau, C1
Guerlais, M1
Jolliet, P1
Bielau, H1
Steiner, J1
Mawrin, C1
Trübner, K1
Brisch, R1
Meyer-Lotz, G1
Brodhun, M1
Dobrowolny, H1
Baumann, B1
Gos, T1
Bernstein, HG1
Bogerts, B1
Saricicek, A1
Savica, R1
Beghi, E1
Mazzaglia, G1
Innocenti, F1
Brignoli, O1
Cricelli, C1
Caputi, AP1
Musolino, R1
Spina, E1
Trifirò, G1
Baillieux, H1
Verslegers, W1
Paquier, P1
De Deyn, PP1
Mariën, P1
Sheard, MH1
Berrettini, WH2
Goldin, LR1
Nurnberger, JI2
Gershon, ES2
Hare, TA1
Simmons-Alling, S1
Post, RM3
Emrich, HM1
Altmann, H1
Dose, M1
von Zerssen, D1
Shinohara, M1
Kariya, T2
Petty, F5
Goddard, AW1
Narayan, M1
Woods, SW1
Germine, M1
Kramer, GL4
Davis, LL2
Yonkers, KA1
Negri, L1
Terranova, R1
Gilotta, SM1
Luca, S1
Prosser, J1
Hughes, CW1
Sheikha, S1
Kowatch, RA1
Rosenbarger, N1
Trent, J1
Vaquerizo, J1
Romero-Rodríguez, JC1
González-Roncero, A1
Gómez-Marcos, A1
Ghaemi, SN1
Katzow, JJ1
Desai, SP1
Goodwin, FK1
Shiah, IS1
Yatham, LN1
Serretti, A1
Macciardi, F1
Cusin, C1
Lattuada, E1
Lilli, R1
Di Bella, D1
Catalano, M1
Smeraldi, E1
Fulton, M1
Kram, M1
Rush, AJ2
Greenberg, DB1
Jonasch, E1
Gadd, MA1
Ryan, BF1
Everett, JR1
Sober, AJ1
Mihm, MA1
Tanabe, KK1
Ott, M1
Haluska, FG1
Frye, MA2
Ketter, TA2
Kimbrell, TA1
Dunn, RT1
Speer, AM2
Osuch, EA2
Luckenbaugh, DA2
Cora-Ocatelli, G1
Leverich, GS2
Iqbal, MM1
Gundlapalli, SP1
Ryan, WG1
Ryals, T1
Passman, TE1
Goldberg, JF1
Burdick, KE1
Megna, JL1
Devitt, PJ1
Sauro, MD1
Dewan, MJ1
Obrocea, GV1
Dunn, RM1
Jajodia, K1
Bozikas, V1
Petrikis, P1
Gamvrula, K1
Savvidou, I1
Karavatos, A1
Hurley, SC1
Blumberg, H1
Anand, A1
Charney, DS1
Marek, G1
Goddard, A1
Mason, GF1
Sachs, GS1
Cosgrove, VE1
Roy, A1
DeJong, J1
Lamparski, D1
George, T1
Linnoila, M1
Dunnam, D1
Ciu, Z1
Gao, BL1
Mitsushio, H1
Takashima, M1
Mataga, N1
Toru, M1
Motohashi, N1
Ikawa, K1
Lloyd, KG1
Morselli, PL1
Bartholini, G1
Suzdak, PD1
Gianutsos, G1
Lerer, B1
Shapira, B1
Waintraub, L1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder[NCT02777372]Phase 484 participants (Actual)Interventional2016-04-01Completed
Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179]Phase 3200 participants (Anticipated)Interventional2021-03-01Recruiting
Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776]Phase 488 participants (Anticipated)Interventional2018-04-03Enrolling by invitation
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]Phase 2236 participants (Anticipated)Interventional2015-12-31Active, not recruiting
Remote Effects of Stroke on Cerebral Metabolism. Evaluation With Positron Emission Tomography and Proton Magnetic Resonance Spectroscopy[NCT00063180]70 participants Observational2003-06-19Completed
Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763]Phase 431 participants (Actual)Interventional2010-06-30Completed
Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867]Phase 40 participants (Actual)Interventional2019-03-22Withdrawn (stopped due to Inability to recruit patients)
Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders[NCT00001482]Phase 260 participants Interventional1995-05-31Completed
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776]Phase 254 participants (Actual)Interventional2017-08-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acoustic Startle Response (ASR) Magnitude Based on Menstrual Cycle Phase

Acoustic startle response (ASR) is measured during the follicular and luteal phase of the menstrual cycle in controls and those with PMDD. Magnitude of ASR is measured using the eyeblink reflex, by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. For the primary outcome of baseline ASR magnitude over the menstrual cycle, peak amplitude of the blink reflex was determined in the 20-120-ms time frame following stimulus onset relative to baseline (baseline is the average baseline electromyography (EMG) level for the 50 ms immediately preceding auditory stimulus onset). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 1 (Follicular), Month 2 (Luteal)

,
Interventiont score (Mean)
Month 1 (Follicular)Month 2 (Luteal)
Control54.256.4
Sertraline53.753.3

Impact of Sertraline on ASR Magnitude

This outcome examines the impact of luteal phase treatment with a selective serotonin reuptake inhibitor (SSRI) (PMDD group only) on acoustic startle response (ASR). ASR is measured using the eyeblink reflex, measured by recording activity from the orbicularis oculi muscle. Recording is performed via two surface disk electrodes (Ag-AgCl) applied underneath the left eye; one in line with the pupil and one 1-2 cm lateral to the first one. Peak amplitude of the blink reflex is determined in the 20-120-ms time frame following stimulus onset. PMDD participants complete test day 3 (Luteal Month 3) while on sertraline and their ASR magnitude will be compared to their previous luteal test day (Luteal Month 2). ASR is measured in microvolts, and raw ASR results are standardized to t-scores. Higher ASR t-score indicates greater contraction of the the orbicularis oculi muscle. A t-score of 50 indicates the population mean with a standard deviation of 10. (NCT02777372)
Timeframe: Month 2 (Luteal), Month 3 (Luteal)

,
Interventiont score (Mean)
Month 2 (Luteal)Month 3 (Luteal)
Control56.451.8
Sertraline53.352.2

Interleukin 6 (IL-6) Level

Blood samples were collected to measure serum interleukin-6 (IL-6). IL-6 levels were compared in the follicular and luteal phases, between Control and PMDD groups. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )

,
Interventionpicogram/milliliter (pg/mL) (Mean)
Month 1 (Follicular)Month 2 (Luteal)
Control0.4.59
Sertraline.34.4

Tumor Necrosis Factor Alpha (TNF-alpha) Level

Blood samples were collected to measure serum TNF-alpha levels in the Follicular and Luteal 1 phases. Levels are measured in picogram/milliliter (pg/mL). (NCT02777372)
Timeframe: Month 1 (Follicular ), Month 2 (Luteal )

,
Interventionpg/mL (Mean)
Month 1 (Follicular )Month 2 (Luteal )
Control1.271.27
Sertraline1.631.54

Hamilton Rating Scale for Depression (HRSD) Improvement

The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)

InterventionHRSD units (Mean)
Ketamine7.82
Methohexital8.60

Prefrontal GABA+ Concentrations

Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine3.90
Gabapentin3.93
Placebo Oral Tablet3.73

Prefrontal Glx Concentrations

Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition

Interventionmmol/kg (Mean)
N-Acetylcysteine21.59
Gabapentin21.69
Placebo Oral Tablet22.25

Reviews

37 reviews available for gamma-aminobutyric acid and Affective Disorders

ArticleYear
Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
    Biological psychiatry, 2023, 01-15, Volume: 93, Issue:2

    Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders; Proton Magnetic Resona

2023
The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
    Schizophrenia research, 2022, Volume: 249

    Topics: Brain; Cognitive Dysfunction; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Spe

2022
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
    Drug discovery today, 2019, Volume: 24, Issue:2

    Topics: Animals; Antidepressive Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders

2019
Morphological changes of the brain in mood disorders.
    Psychiatria polska, 2018, Oct-27, Volume: 52, Issue:5

    Topics: Bipolar Disorder; Brain; gamma-Aminobutyric Acid; Humans; Mood Disorders; Neuroimaging; Neurons

2018
Biomarkers of psychiatric diseases: current status and future prospects.
    Metabolism: clinical and experimental, 2015, Volume: 64, Issue:3 Suppl 1

    Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph

2015
Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
    Current psychiatry reports, 2015, Volume: 17, Issue:11

    Topics: Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Disorders; Disease Management;

2015
Gene Targeting Studies of Hyperexcitability and Affective States of Alcohol Withdrawal in Rodents.
    International review of neurobiology, 2016, Volume: 126

    Topics: Alcoholism; Animals; Animals, Genetically Modified; Disease Models, Animal; Epilepsy; gamma-Aminobut

2016
Catatonia.
    CNS spectrums, 2016, Volume: 21, Issue:4

    Topics: Benzodiazepines; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive

2016
[Mood stabilizers--past, present and future].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:1

    Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino

2008
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.
    Current opinion in pharmacology, 2009, Volume: 9, Issue:1

    Topics: Animals; Brain; Fluoxetine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Mood Disorders; Pregn

2009
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Neuropharmacology, 2012, Volume: 62, Issue:1

    Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc

2012
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Neuropharmacology, 2012, Volume: 62, Issue:1

    Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc

2012
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Neuropharmacology, 2012, Volume: 62, Issue:1

    Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc

2012
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Neuropharmacology, 2012, Volume: 62, Issue:1

    Topics: Animals; Antidepressive Agents; Brain; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Glucoc

2012
Pharmacotherapy of fibromyalgia.
    Best practice & research. Clinical rheumatology, 2011, Volume: 25, Issue:2

    Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine H

2011
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
    Brain research, 2012, Oct-02, Volume: 1476

    Topics: Animals; Antidepressive Agents; Behavioral Symptoms; Cognition Disorders; gamma-Aminobutyric Acid; G

2012
Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 3

    Topics: Anxiety Disorders; Brain; Brain Chemistry; Creatine; Depressive Disorder; Epilepsy; GABA Agents; gam

2003
GABA and mood disorders.
    Psychological medicine, 2003, Volume: 33, Issue:3

    Topics: Brain; gamma-Aminobutyric Acid; Humans; Limbic System; Magnetic Resonance Spectroscopy; Mood Disorde

2003
GABAergic dysfunction in mood disorders.
    Molecular psychiatry, 2003, Volume: 8, Issue:8

    Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Mood Disorders

2003
Assessment and treatment of hot flushes and menopausal mood disturbance.
    The Psychiatric clinics of North America, 2003, Volume: 26, Issue:3

    Topics: Acetates; Aging; Amines; Anti-Anxiety Agents; Cognition Disorders; Cyclohexanecarboxylic Acids; Fema

2003
Clinical studies implementing glutamate neurotransmission in mood disorders.
    Annals of the New York Academy of Sciences, 2003, Volume: 1003

    Topics: Animals; Brain Chemistry; Depression; gamma-Aminobutyric Acid; Glutamates; Humans; Magnetic Resonanc

2003
GABA and glutamate systems as therapeutic targets in depression and mood disorders.
    Expert opinion on therapeutic targets, 2005, Volume: 9, Issue:1

    Topics: Animals; Antidepressive Agents; Depressive Disorder; Drug Delivery Systems; Excitatory Amino Acid An

2005
Major affective disorders and schizophrenia: a common molecular signature?
    Human mutation, 2006, Volume: 27, Issue:9

    Topics: Dopamine; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; Humans; Mood Di

2006
GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
    CNS & neurological disorders drug targets, 2007, Volume: 6, Issue:2

    Topics: Affect; Animals; Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Agonists; Excitat

2007
Clinical pharmacology of aggressive behavior.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Aged; Aggression; Anger; Anti-Anxiety Agents; Benzodiazepines; Brain Chemistry; C

1984
Genetic factors in affective illness.
    Journal of psychiatric research, 1984, Volume: 18, Issue:4

    Topics: ABO Blood-Group System; Blood Platelets; Cholinergic Fibers; Diseases in Twins; Female; gamma-Aminob

1984
[Etiology of affective disorders].
    Nihon rinsho. Japanese journal of clinical medicine, 1994, Volume: 52, Issue:5

    Topics: Animals; gamma-Aminobutyric Acid; Humans; Mood Disorders; Neuropeptides; Neurosecretory Systems; Neu

1994
GABA and mood disorders: a brief review and hypothesis.
    Journal of affective disorders, 1995, Aug-18, Volume: 34, Issue:4

    Topics: Biomarkers; Bipolar Disorder; Brain Stem; Depressive Disorder; gamma-Aminobutyric Acid; Hippocampus;

1995
The association between premenstrual dysphoric disorder and other mood disorders.
    The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 15

    Topics: Biomarkers; Comorbidity; Depressive Disorder; Diagnosis, Differential; Endorphins; Family; Female; g

1997
GABA function in mood disorders: an update and critical review.
    Life sciences, 1998, Volume: 63, Issue:15

    Topics: Animals; Antidepressive Agents; Antimanic Agents; Electroconvulsive Therapy; gamma-Aminobutyric Acid

1998
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
    Cancer, 2000, Jul-15, Volume: 89, Issue:2

    Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antimanic Agents; Antineoplastic Agents; Bipolar Disor

2000
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
    Southern medical journal, 2001, Volume: 94, Issue:3

    Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed

2001
Cognitive side effects of anticonvulsants.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 14

    Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane

2001
Lamotrigine update and its use in mood disorders.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:5

    Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids;

2002
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
    Molecular psychiatry, 2002, Volume: 7 Suppl 1

    Topics: Antidepressive Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Models, Neurological; Mood Di

2002
Bipolar disorder: current treatments and new strategies.
    Cleveland Clinic journal of medicine, 1998, Volume: 65 Suppl 1

    Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent

1998
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
    Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1990, Volume: 23, Issue:4

    Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy;

1990
GABA and affective disorders.
    Medical biology, 1987, Volume: 65, Issue:2-3

    Topics: Animals; Antidepressive Agents; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Mood Disord

1987
Neurochemical mechanisms of mood stabilization. Focus on electroconvulsive therapy.
    Annals of the New York Academy of Sciences, 1986, Volume: 462

    Topics: Acetylcholine; Antidepressive Agents; Brain; Choline O-Acetyltransferase; Electroconvulsive Therapy;

1986
[GABA and mood disorders].
    L'Encephale, 1987, Volume: 13 Spec No

    Topics: 4-Aminobutyrate Transaminase; Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid;

1987

Trials

14 trials available for gamma-aminobutyric acid and Affective Disorders

ArticleYear
Abnormal GABAergic function and negative affect in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:4

    Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans

2014
Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil.
    Annals of medicine, 2015, Volume: 47, Issue:3

    Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric

2015
Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain.
    Pain, 2010, Volume: 149, Issue:2

    Topics: Activities of Daily Living; Adult; Analgesics; Fatigue Syndrome, Chronic; Female; Fibromyalgia; gamm

2010
Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.
    Expert opinion on drug safety, 2012, Volume: 11, Issue:6

    Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Depressive

2012
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
    Pain, 2004, Volume: 109, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, D

2004
Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.
    Epilepsy & behavior : E&B, 2005, Volume: 6, Issue:3

    Topics: Adult; Anticonvulsants; Chi-Square Distribution; Demography; Drug Therapy, Combination; Epilepsy; Fe

2005
Treatment of tinnitus with gabapentin: a pilot study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2007, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Auditory Threshold; Cyclohexanecarbo

2007
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
    Pharmacology, biochemistry, and behavior, 1983, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as

1983
Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:11A

    Topics: Adult; Blood Pressure; Double-Blind Method; Female; gamma-Aminobutyric Acid; Heart Rate; Humans; Mal

1997
Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:11A

    Topics: Adjustment Disorders; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Meth

1997
Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders: a preliminary study.
    Journal of child and adolescent psychopharmacology, 1997, Volume: 7, Issue:3

    Topics: Adolescent; Child; Child Behavior Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Mood Dis

1997
A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:6

    Topics: Acetates; Adult; Amines; Antimanic Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-B

2000
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:1

    Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty

2002
Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders.
    Biological psychiatry, 2002, Feb-01, Volume: 51, Issue:3

    Topics: Acetates; Adult; Aged; Amines; Antidepressive Agents; Cross-Over Studies; Cross-Sectional Studies; C

2002

Other Studies

28 other studies available for gamma-aminobutyric acid and Affective Disorders

ArticleYear
GABA
    Current topics in behavioral neurosciences, 2022, Volume: 52

    Topics: Anxiety; Anxiety Disorders; gamma-Aminobutyric Acid; Humans; Mood Disorders; Receptors, GABA; Recept

2022
Enrichment Environment Positively Influences Depression- and Anxiety-Like Behavior in Serotonin Transporter Knockout Rats through the Modulation of Neuroplasticity, Spine, and GABAergic Markers.
    Genes, 2020, 10-23, Volume: 11, Issue:11

    Topics: Animals; Animals, Genetically Modified; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic

2020
Glutamate and GABA contributions to medial prefrontal cortical activity to emotion: implications for mood disorders.
    Psychiatry research, 2014, Sep-30, Volume: 223, Issue:3

    Topics: Adult; Anger; Emotions; Facial Expression; Fear; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyr

2014
Gabapentin Enhances Neurogenesis in E14 Rat Embryonic Neocortex Stem Cells.
    Drug research, 2015, Volume: 65, Issue:8

    Topics: Amines; Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclohexanecarboxylic Ac

2015
Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders.
    Molecular psychiatry, 2016, Volume: 21, Issue:3

    Topics: Analysis of Variance; Case-Control Studies; Databases, Factual; Female; gamma-Aminobutyric Acid; Gen

2016
A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression.
    Neuroscience letters, 2016, Mar-11, Volume: 616

    Topics: Aged; Aged, 80 and over; Amino Acids; Bipolar Disorder; Body Fluids; Case-Control Studies; Chromatog

2016
Functional role of cortical astrocytes in sleep/affective dysregulation under the chronic pain: analysis by artificial control of astrocytes using optogenetics.
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2016, Volume: 148, Issue:3

    Topics: Animals; Astrocytes; Chronic Pain; gamma-Aminobutyric Acid; Humans; Mood Disorders; Optogenetics; Sl

2016
Calcium binding proteins immunoreactivity in the rat basolateral amygdala following myocardial infarction.
    Cellular and molecular neurobiology, 2010, Volume: 30, Issue:3

    Topics: Amygdala; Animals; Biomarkers; Brain Mapping; Calbindin 2; Calbindins; Calcium-Binding Proteins; Dep

2010
Association of the GABRD gene and childhood-onset mood disorders.
    Genes, brain, and behavior, 2010, Volume: 9, Issue:6

    Topics: Adolescent; Age of Onset; Female; gamma-Aminobutyric Acid; Genotype; Haplotypes; Humans; Hungary; Li

2010
GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders.
    The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:6

    Topics: Adult; Age Factors; Aged; Biomarkers; Bipolar Disorder; Down-Regulation; Female; gamma-Aminobutyric

2011
Anorgasmia and withdrawal syndrome in a woman taking gabapentin.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:2

    Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H

2003
Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders.
    Neuroscience letters, 2003, Sep-25, Volume: 349, Issue:1

    Topics: Adult; Brain; Brain Chemistry; Chromosomes, Human, Pair 5; DNA Mutational Analysis; Female; gamma-Am

2003
Abuse, dependency and withdrawal with gabapentin: a first case report.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:1

    Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A

2007
Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study.
    Annals of the New York Academy of Sciences, 2007, Volume: 1096

    Topics: Aged; Bipolar Disorder; Brain; Brain Mapping; Female; gamma-Aminobutyric Acid; Gene Expression Regul

2007
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
    European journal of neurology, 2007, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H

2007
Cerebellar cognitive affective syndrome associated with topiramate.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:5

    Topics: Amines; Anticonvulsants; Carbamazepine; Cerebellar Diseases; Cerebellum; Cognition Disorders; Cycloh

2008
Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate.
    Biological psychiatry, 1983, Volume: 18, Issue:2

    Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Humans; Lithium; Lith

1983
Plasma levels of gamma-aminobutyric acid and panic disorder.
    Psychiatry research, 1996, Jul-31, Volume: 63, Issue:2-3

    Topics: Adult; Agoraphobia; Anxiety Disorders; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; M

1996
[Partial complex status epilepticus: diagnostic difficulties].
    Revista de neurologia, 1998, Volume: 26, Issue:154

    Topics: Anticonvulsants; Child; Crime; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalog

1998
Gabapentin treatment of mood disorders: a preliminary study.
    The Journal of clinical psychiatry, 1998, Volume: 59, Issue:8

    Topics: Acetates; Adolescent; Adult; Aged; Ambulatory Care; Amines; Anticonvulsants; Antidepressive Agents;

1998
GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders.
    Psychiatric genetics, 1998,Winter, Volume: 8, Issue:4

    Topics: Adult; Anxiety; Bipolar Disorder; Delusions; Depression; DNA; Female; gamma-Aminobutyric Acid; Genet

1998
Evidence for the segregation of a major gene for human plasma GABA levels.
    Molecular psychiatry, 1999, Volume: 4, Issue:6

    Topics: Adolescent; Adult; Chromosome Segregation; Family Health; Female; gamma-Aminobutyric Acid; Genes, Re

1999
Treatment of alcohol withdrawal with gabapentin.
    Progress in neuro-psychopharmacology & biological psychiatry, 2002, Volume: 26, Issue:1

    Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Ethanol; Gabapentin; gamm

2002
Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables.
    Archives of general psychiatry, 1991, Volume: 48, Issue:5

    Topics: Adult; Age Factors; Alcohol Drinking; Alcoholism; Anxiety Disorders; Depressive Disorder; Divorce; D

1991
Plasma GABA in mood disorders.
    Psychopharmacology bulletin, 1990, Volume: 26, Issue:2

    Topics: Affective Disorders, Psychotic; gamma-Aminobutyric Acid; Humans; Mood Disorders

1990
Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
    The Journal of pharmacology and experimental therapeutics, 1988, Volume: 245, Issue:3

    Topics: Animals; Body Weight; Brain Chemistry; Carbamazepine; Dopamine; Dose-Response Relationship, Drug; ga

1988
GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders?
    European journal of pharmacology, 1989, Jul-04, Volume: 166, Issue:1

    Topics: Animals; Baclofen; Carbamazepine; Cerebral Cortex; gamma-Aminobutyric Acid; Hippocampus; Lithium; Ma

1989
Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs. A possible role in affective disorders.
    Neuropharmacology, 1985, Volume: 24, Issue:3

    Topics: Animals; Anticonvulsants; Antidepressive Agents; Baclofen; Cerebral Cortex; Dihydroalprenolol; gamma

1985